Biology of Blood and Marrow Transplantation
Volume 16, Issue 2 , Pages 147-156, February 2010

The National Marrow Donor Program's Symposium on Patient Advocacy in Cellular Transplantation Therapy: Addressing Barriers to Hematopoietic Cell Transplantation

  • Elizabeth A. Murphy

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
    • Corresponding Author InformationCorrespondence and reprint requests: Elizabeth A. Murphy, EdD, RN, National Marrow Donor Program, Office of Patient Advocacy, 3001 Broadway NE, Suite 100, Minneapolis, MN 55413.
  • ,
  • Stacy Stickney Ferguson

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
  • ,
  • Nancy Atieno Omondi

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
  • ,
  • Lisa C. Getzendaner

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
  • ,
  • James L. Gajewski

      Affiliations

    • Oregon Health and Science University, Portland, Oregon
  • ,
  • Gary A. Goldstein

      Affiliations

    • Stanford Hospital and Clinics, Stanford, California
  • ,
  • John R. Wingard

      Affiliations

    • University of Florida, Gainesville, Florida
  • ,
  • J. Douglas Rizzo

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin
    • Medical College of Wisconsin, Milwaukee, Wisconsin
  • ,
  • Navneet S. Mahjail

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota
    • University of Minnesota, Minneapolis, Minnesota

Received 13 May 2009; accepted 10 August 2009. published online 07 September 2009.

Although hematopoietic cell transplantation (HCT) is an effective treatment option for patients with life-threatening blood, immune system, or genetic disorders, many barriers besides a lack of suitably matched donors exist and can have an adverse impact on access and outcomes of HCT. In 2008, the National Marrow Donor Program, through its Office of Patient Advocacy, convened a diverse group of experts and transplantation survivors to identify persistent patient barriers throughout the transplantation process and to make recommendations for programs and initiatives to address these barriers, including new research opportunities. This group included transplantation physicians and other health care providers, relevant subject experts, and representatives from transplantation centers and patient advocacy organizations. Working groups were formed to identify patient barriers to HCT and to recommend and prioritize initiatives as they relate to the pretransplantation period, the early posttransplantation period, long-term survivorship, financial issues, and special populations. This report summarizes the symposium's deliberations and recommendations to address persistent patient barriers throughout the transplantation process.

Key Words: Hematopoietic stem cell transplantation, Quality of life, Barriers to transplantation, Patient advocacy, Health disparities, Survivorship, Financial barriers, National Marrow Donor Program

 

 Financial disclosure: See Acknowledgments on page 154.

PII: S1083-8791(09)00370-X

doi:10.1016/j.bbmt.2009.08.004

Refers to erratum:

  • Erratum

    Biology of Blood and Marrow Transplantation December 2010 (Vol. 16, Issue 12, Page 1752)

Biology of Blood and Marrow Transplantation
Volume 16, Issue 2 , Pages 147-156, February 2010